QED Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Palo Alto CA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03773302
First Marketed Drug
2021
infigratinib (Truseltiq)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

QED THERAP | QED Therapeutics | QED Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

infigratinib (Truseltiq) (2021)

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

infigratinib (Truseltiq) (7 trials)

Drugs in Phase 1 Trials (3)

iohexol (Omnipaque) (1 trial)

iopamidol (Isovue) (1 trial)

tamoxifen (nolvadex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Achondroplasia (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Cholangiocarcinoma (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6